Novo Nordisk As Stock Performance
NVO Stock | USD 124.53 1.08 0.87% |
On a scale of 0 to 100, Novo Nordisk holds a performance score of 10. The company secures a Beta (Market Risk) of 0.61, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Novo Nordisk's returns are expected to increase less than the market. However, during the bear market, the loss of holding Novo Nordisk is expected to be smaller as well. Please check Novo Nordisk's semi variance, as well as the relationship between the rate of daily change and relative strength index , to make a quick decision on whether Novo Nordisk's current price movements will revert.
Risk-Adjusted Performance
10 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Novo Nordisk AS are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of very conflicting basic indicators, Novo Nordisk displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.87 | Five Day Return (1.74) | Year To Date Return 21.96 | Ten Year Return 459.18 | All Time Return 77.7 K |
Forward Dividend Yield 0.0111 | Payout Ratio 0.027 | Last Split Factor 2:1 | Forward Dividend Rate 1.37 | Dividend Date 2024-04-02 |
Novo Nordisk dividend paid on 2nd of April 2024 | 04/02/2024 |
1 | Costco Now Offering Ozempic Prescriptions | 04/03/2024 |
2 | My Doctor Prescribed Me A Weight Loss Drug. Heres How It Ended Up In The Trash. | 04/09/2024 |
3 | Ginkgo Bioworks and Novo Nordisk Expand Alliance to Collaborate Across RD Value Chain | 04/10/2024 |
4 | UPDATE 2-Gerresheimer expects sales boost from burgeoning obesity drugs sector | 04/11/2024 |
5 | 5 stocks to watch on Friday JPM, BLK, STT and more | 04/12/2024 |
6 | How big is the GLP-1 market Exploring its growth potential | 04/15/2024 |
Begin Period Cash Flow | 12.7 B |
Novo |
Novo Nordisk Relative Risk vs. Return Landscape
If you would invest 10,641 in Novo Nordisk AS on January 19, 2024 and sell it today you would earn a total of 1,812 from holding Novo Nordisk AS or generate 17.03% return on investment over 90 days. Novo Nordisk AS is generating 0.2685% of daily returns assuming volatility of 1.9673% on return distribution over 90 days investment horizon. In other words, 17% of stocks are less volatile than Novo, and above 95% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
Risk |
Novo Nordisk Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Novo Nordisk's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Novo Nordisk AS, and traders can use it to determine the average amount a Novo Nordisk's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1365
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | NVO | |||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns |
Estimated Market Risk
1.97 actual daily | 17 83% of assets are more volatile |
Expected Return
0.27 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
0.14 actual daily | 10 90% of assets perform better |
Based on monthly moving average Novo Nordisk is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Novo Nordisk by adding it to a well-diversified portfolio.
Novo Nordisk Fundamentals Growth
Novo Stock prices reflect investors' perceptions of the future prospects and financial health of Novo Nordisk, and Novo Nordisk fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Novo Stock performance.
Return On Equity | 0.88 | ||||
Return On Asset | 0.23 | ||||
Profit Margin | 0.36 % | ||||
Operating Margin | 0.43 % | ||||
Current Valuation | 547.15 B | ||||
Shares Outstanding | 4.46 B | ||||
Price To Earning | 37.42 X | ||||
Price To Book | 36.21 X | ||||
Price To Sales | 2.43 X | ||||
Revenue | 232.26 B | ||||
Gross Profit | 148.51 B | ||||
EBITDA | 112.94 B | ||||
Net Income | 83.68 B | ||||
Cash And Equivalents | 37.47 B | ||||
Cash Per Share | 16.57 X | ||||
Total Debt | 27.01 B | ||||
Debt To Equity | 0.34 % | ||||
Current Ratio | 0.92 X | ||||
Book Value Per Share | 23.90 X | ||||
Cash Flow From Operations | 108.91 B | ||||
Earnings Per Share | 2.65 X | ||||
Market Capitalization | 551.2 B | ||||
Total Asset | 314.49 B | ||||
Retained Earnings | 104.84 B | ||||
Working Capital | (30.01 B) | ||||
Current Asset | 8.03 B | ||||
Current Liabilities | 5.95 B | ||||
About Novo Nordisk Performance
To evaluate Novo Nordisk AS Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Novo Nordisk generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Novo Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Novo Nordisk AS market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Novo's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Last Reported | Projected for Next Year | ||
Days Of Inventory On Hand | 324.65 | 214.02 | |
Return On Tangible Assets | 0.33 | 0.35 | |
Return On Capital Employed | 0.71 | 0.74 | |
Return On Assets | 0.27 | 0.14 | |
Return On Equity | 0.79 | 0.82 |
Things to note about Novo Nordisk AS performance evaluation
Checking the ongoing alerts about Novo Nordisk for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Novo Nordisk AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.The company has 27.01 B in debt with debt to equity (D/E) ratio of 0.34, which is OK given its current industry classification. Novo Nordisk AS has a current ratio of 0.9, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Debt can assist Novo Nordisk until it has trouble settling it off, either with new capital or with free cash flow. So, Novo Nordisk's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Novo Nordisk AS sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Novo to invest in growth at high rates of return. When we think about Novo Nordisk's use of debt, we should always consider it together with cash and equity. | |
Novo Nordisk AS has a poor financial position based on the latest SEC disclosures | |
On 2nd of April 2024 Novo Nordisk paid $ 0.6638 per share dividend to its current shareholders | |
Latest headline from investing.com: How big is the GLP-1 market Exploring its growth potential |
- Analyzing Novo Nordisk's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Novo Nordisk's stock is overvalued or undervalued compared to its peers.
- Examining Novo Nordisk's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Novo Nordisk's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Novo Nordisk's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Novo Nordisk's stock. These opinions can provide insight into Novo Nordisk's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Complementary Tools for Novo Stock analysis
When running Novo Nordisk's price analysis, check to measure Novo Nordisk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novo Nordisk is operating at the current time. Most of Novo Nordisk's value examination focuses on studying past and present price action to predict the probability of Novo Nordisk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novo Nordisk's price. Additionally, you may evaluate how the addition of Novo Nordisk to your portfolios can decrease your overall portfolio volatility.
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Transaction History View history of all your transactions and understand their impact on performance | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum |
Is Novo Nordisk's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.631 | Dividend Share 9.4 | Earnings Share 2.65 | Revenue Per Share 51.812 | Quarterly Revenue Growth 0.37 |
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.